Marker Therapeutics
MRKR
63 hedge funds and large institutions have $29.4M invested in Marker Therapeutics in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 10 closing their positions.
2,068% more call options, than puts
Call options by funds: $542K | Put options by funds: $25K
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
4% more capital invested
Capital invested by funds: $28.3M → $29.4M (+$1.1M)
1.48% less ownership
Funds ownership: 32.01% → 30.53% (-1.5%)
3% less funds holding
Funds holding: 65 → 63 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$488K |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$269K |
| 3 |
Renaissance Technologies
New York
|
+$186K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$145K |
| 5 |
BlackRock
New York
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$2.69M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$197K |
| 3 |
State Street
Boston,
Massachusetts
|
-$112K |
| 4 |
VWM
Vigilare Wealth Management
Scottsdale,
Arizona
|
-$110K |
| 5 |
D.E. Shaw & Co
New York
|
-$67K |
MRKR Hedge Fund Activity: Q2 2020 in Review
63 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2020, worth a combined $29.4M — up 3.9% from $28.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MRKR and 8 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 20 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $488K. The largest seller was Baker Bros. Advisors, cutting an estimated $2.69M.
- 63 institutional investors held Marker Therapeutics (MRKR) as of Q2 2020, down from 65 in Q1 2020.
- Funds reported $29.4M of Marker Therapeutics stock for Q2 2020, up 3.9% quarter-over-quarter.
- 8 funds opened new Marker Therapeutics positions in Q2 2020 and 10 closed out, a net change of -2 holders.
- The largest Marker Therapeutics buyer in Q2 2020 was Bridgeway Capital Management, an estimated $488K added.
- The largest Marker Therapeutics seller in Q2 2020 was Baker Bros. Advisors, an estimated $2.69M sold.
Based on aggregated 13F filings for Q2 2020.